Clinical Trial Update: A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease [Phase 3]

View source ↗

Summary

Phase 3 safety study of Vatiquinone (PTC743) in previously treated participants with inherited mitochondrial disease has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inherited Mitochondrial Disease

Drugs mentioned

• Vatiquinone

Snippet

Sponsor: PTC Therapeutics | Conditions: Inherited Mitochondrial Disease | Phase 3 | Status: COMPLETED | Results posted: 2025-12-22